Former UCLA Decathlete Sentenced to 17.5 Years in Jail for Securities Fraud

Nov.22.2022
Former UCLA Decathlete Sentenced to 17.5 Years in Jail for Securities Fraud
Former UCLA decathlete sentenced to 210 months in prison for defrauding investors of over $45 million.

LOS ANGELES – A former decathlete from the University of California, Los Angeles who once competed for the Philippine national team was sentenced to 210 months in prison today for fraudulently raising over $45 million from investors. These investors were told their funds would be used to support a company marketing cannabis e-cigarettes.


David Joseph Bunevacz, 53 years old from the city of Calabasas, has been sentenced by US District Judge Dale S. Fischer to pay $35,267,851 in restitution. During today's sentencing hearing, Judge Fischer noted that Bunevacz had "bullied those who thought he was their friend," and that the severity of his actions cannot be measured solely in monetary terms.


Judge Fischer also found that even during the probationary period following his conviction in state court, Bunevacz continued to carry out his plan and concluded that "neither criminal conviction nor threat of imprisonment could persuade [Bunevacz] to become a law-abiding citizen.


On July 18th, Bunevacz admitted to committing securities fraud and telecommunications fraud. He has been in federal custody since his arrest on April 5th in connection to this case.


Going back to 2010, Bunevacz created various business entities, including CB Holding Group Corp. and Caesarbrutus LLC, which he claimed were involved in the marijuana industry and the sale of electronic cigarettes containing marijuana products such as CBD oil and THC.


Bunevacz reportedly lied to at least one investor about his supposed long-term partnership with a Chinese manufacturer of disposable e-cigarettes. According to court documents, he claimed to have obtained "pesticide-free raw material oil" that was sent to a laboratory for flavor infusion using a "proprietary custom process" to make vape flavoring smooth and discrete. He also provided fake documents such as bank statements, invoices, and purchase orders to support his claims of the company's success and need for investor funding.


Bunevacz did not use these funds to provide financial support for the operation of his business - despite the fact that some of his victims are currently experiencing serious financial difficulties. Instead, he diverted the vast majority of the funds to finance his own luxurious lifestyle, which includes a mansion in Calabasas, trips to Las Vegas, expensive jewelry and designer handbags, extravagant birthday parties for his daughter, and horses.


To create the appearance of conducting legitimate business activities for his company, Bunevacz registered various shell companies, including several with similar or identical names to legitimate marijuana businesses. To conceal his control over these shell companies and related bank accounts, Bunevacz listed other individuals, including his stepdaughter, as executives of the shell companies.


Bunevacz's blog praises his success as a former decathlete competing in the Philippines, and highlights appearances of his wife and daughter on a reality show. According to sworn statements submitted in support of the criminal prosecution, despite promoting his background, Bunevacz made efforts to conceal negative information from investors, such as his conviction for a felony in 2017 for illegally selling securities.


After an investor discovered a lawsuit against Bunevacz, the latter sent a forged version of a settlement agreement via email, claiming he had received $325,000 as part of the settlement. However, in reality, it was Bunevacz who agreed to pay $325,000 to settle the claim.


According to government records, Bunevacz raised approximately $45,227,266 from over 100 victim investors through his marijuana company. Judge Fischer found that Bunevacz caused approximately $35,267,851 in losses.


A prosecutor argued in a sentencing memorandum that "the violation of personal dignity, emotional harm, and lasting trauma caused by [Bunevacz] are reminiscent of the harm typically associated with violent crimes." "Furthermore, [Bunevacz] victimized over 100 individuals, causing harm on a scale rarely seen.


The Federal Bureau of Investigation, the Criminal Investigation Division of the Internal Revenue Service, and the Los Angeles County Sheriff's Department conducted an investigation into the matter. The Securities and Exchange Commission provided significant assistance. Assistant U.S. Attorney Alexander B. Schwab of the Major Frauds Section filed charges in this case.


Statement:


This article is based on third-party information that has been translated using machine translation, and is only intended for exchange and learning within the industry.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of its content. The translation of this article is only intended for industry communication and research purposes.


Due to limitations in the translation process, the translated article may not fully reflect the intended meaning of the original. Please refer to the original text for accuracy.


2FIRSTS maintains complete consistency with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The compilation of the information herein is copyrighted by the original media source and author. If infringement occurs, please contact us for prompt removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canadian Health Minister Marjorie Michel says she is not considering loosening retail restrictions on nicotine pouches. Canada regulates pouches containing 4 mg or less of nicotine per unit as non-prescription nicotine replacement therapy and requires newer NRT formats such as pouches to be sold from behind pharmacy counters. Meanwhile, Unsmoke Canada, linked to Philip Morris International's Canadian business, is pushing to allow pouches in convenience stores and other general retail outlets. Health Canada also acknowledges continued unauthorized sales, while recent research shows rising pouch use among Canadian youth aged 16 to 19.
Sep.24
German Customs Seize 115,800 Vapes in €1.4 Million Tax Case
German Customs Seize 115,800 Vapes in €1.4 Million Tax Case
Germany's Magdeburg Main Customs Office seized 115,800 untaxed e-cigarettes containing a combined 4.366 million mL of e-liquid during four truck inspections between August 10 and September 4, 2026. The seizures prevented an estimated €1.397 million in tax losses and set a record for the customs office's jurisdiction. Criminal proceedings have been initiated against four truck drivers. The case follows a separate German investigation involving more than 7.6 million illicit vapes and an estimated €33.3 million in excise-tax losses.
Enforcement
Oct.13
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands (TPB) reported third-quarter 2026 Modern Oral net sales of $74.4 million on November 9, up 102.9% year over year and representing 49.2% of consolidated net sales. Total company net sales rose 27.0% to $151.1 million, while net income attributable to TPB declined 81.4% to $3.93 million. The company is expanding the US retail presence of its FRE and ALP nicotine pouch brands and expects its Modern Oral chain-store footprint to grow by more than 70% during 2026. Selling, general and administrative expenses increased 69.1% to $75.3 million, while PMTA-related expenses reached approximately $3.15 million and manufacturing start-up costs totaled about $593,000. ALP plans to open a branded pop-up in New York City's SoHo neighborhood on November 13, alongside a marketing campaign extending into January 2027. TPB owns 50% of ALP but consolidates the venture in its financial statements.
company
Nov.11
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Complete abstinence is not always the goal of addiction treatment under a harm-reduction approach, Japanese psychiatrist Tomohiro Shirasaka told 2Firsts in Manila. In the interview, he discussed patients' quality of life, Japan's shift towards heated tobacco products, and the challenges of quitting smoking for people with mental illness. Drawing on addiction treatment work in the Philippines, he advocated support rather than punishment and questioned whether fear-based health warnings effectively address the reasons people continue smoking.
Nov.10